Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2013-2017

30 pages report Published in
Pharmaceuticals
Publisher: China Research and Intelligence

arrowFor This Report

In China, PRRS is the most serious disease that impairs the pig raising & breeding industry. It inflicted heavy losses on China pig raising & breeding industry for many times.

In April 2007, Ministry of Agriculture of China issued Technical Standards of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Prevention and Treatment, and classified HP-PRRS into serious animal epidemic diseases which are covered by the national compulsory immunization program. Based on National Compulsory Immunization Plan of Animal Epidemic Diseases 2013, China government conducts compulsory vaccinations for all pigs against HP-PRRS. In order to identify various strains, local governments must take effective measures and ensure every county only use one kind of live HP-PRRS vaccines to immunize pigs.

With the increasing living standards of Chinese people, the demand for pork keeps growing accordingly. In 2012, the output volume of pork in China was 53.35 million tons, increasing by 5.6%. In 2012, China also imported 522,000 tons of pork, increasing by 11.7% YOY. At the end of 2012, the live stock volume of pigs in China was 474.92 million, increasing by 1.6% YOY; the fattened volume was 696.28 million in 2012, increasing by 5.2%. The scale expansion of the pig raising & breeding industry causes increasing demand for PRRS vaccines in China.

At present, more than 20 enterprises are qualified to produce PRRS vaccines in China (about 40 factories). For a long time, only one foreign enterprise Boehringer was approved to enter Chinese market with its PRRS vaccines. In August 2013, live attenuated HP-PRRS vaccines (Ruilan’an) produced in China by Zoetis of Pfizer was officially approved to be launched into Chinese market.

In China, the government provides HP-PRRS vaccines to all pig raising & breeding enterprises and households for free, but there are various problems during vaccine production, transportation, etc. Therefore, many enterprises and households prefer to purchase vaccines, to avoid the occurrence of PRRS. In the next few years, it is predicted that the scale of China pig raising & raising & breeding industry will keep increasing, the intensive raising & breeding mode will be improved and the demand for PRRS vaccines will keep growing. For international animal vaccine producing enterprises, they will find huge market opportunities in China.

Through this report, the readers can acquire the following information:

  • Incidence status and prevention program of porcine reproductive and respiratory syndrome in China
  • China pig raising & breeding industry status
  • Supply and demand status of China porcine reproductive and respiratory syndrome (PRRS) vaccines
  • Factors influencing the market development of porcine reproductive and respiratory syndrome (PRRS) vaccines
  • Porcine reproductive and respiratory syndrome (PRRS) vaccine procurement system of Chinese government
  • Forecast on porcine reproductive and respiratory syndrome (PRRS) vaccine industry

The following enterprises and people are proposed to purchase this report:

  • Animal vaccine production /trade enterprises
  • Pig raising & breeding enterprises
  • Management organizations of the livestock husbandry
  • Investors and research institutes concerned about animal vaccines

Table of Contents


1 Relevant Definitions of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines

1.1 Definition and Incidence Status of Porcine Reproductive and Respiratory Syndrome

1.1.1 Definition of Porcine Reproductive and Respiratory Syndrome

1.1.2 Global Incidence Status of Porcine Reproductive and Respiratory Syndrome

1.2 Classification of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines

1.2.1 Live Attenuated Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

1.2.2 Inactivated Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

1.2.3 Live Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP-PRRS) Vaccine


2. Development Environment of China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2012-2013

2.1 Policy Environment of China Animal Vaccine Industry

2.1.1 Legislation of Animal Epidemic Prevention

2.1.2 Organization Structure

2.1.3 Appropriation Budget of Epidemic Prevention

2.1.4 Compulsory Immunization Program Scope of Porcine Reproductive and Respiratory Syndrome

2.1.5 Safety Precautions of Pig Breeding

2.2 Status of China Pig Raising & Breeding Industry, 2012

2.2.1 Live Stock and Fattened Volume

2.2.2 Characteristics of China Pig Raising & Breeding Industry

2.3 Incidence Status of China Porcine Reproductive and Respiratory Syndrome, 2012-2013


3 Performance of China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2012

3.1 Supply

3.1.1 Supply Status

3.1.2 Factors Influencing Supply

3.2 Demand

3.2.1 Demand Status

3.2.2 Factors Influencing Demand

3.3 Immunization Processes of Porcine Reproductive and Respiratory Syndrome

3.3.1 Immunization Plans of Porcine Reproductive and Respiratory Syndrome

3.3.2 Smuggling of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines

3.3.3 Lot Release System

3.4 Tendering Results of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP-PRRS) Vaccines in Some Regions of China, 2013

3.4.1 Sichuan

3.4.2 Guangdong


4 China Major Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Producing Enterprises, 2012-2013

4.1 Enterprise 1

4.1.1 Enterprise Profile

4.1.2 Producing Status of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines

4.1.3 Enterprise Development Strategies

4.2 Enterprise 2

4.3 Enterprise 3

4.4 Enterprise 4

4.5 Enterprise 5


5 Market Prospective of China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines, 2013-2017

5.1 Factors Influencing Development

5.1.1 Forecast on Government Policies

5.1.2 Forecast on Pig Raising & Breeding Industry

5.2 Supply and Demand Forecast on Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines

5.2.1 Supply Trend

5.2.2 Demand Trend


List of Charts


Chart Global Incidence Status of Porcine Reproductive and Respiratory Syndrome, 2012

Chart China Live Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Producing Enterprises

Chart China Inactivated Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Producing Enterprises

Chart China Live Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP-PRRS) Vaccine Producing Enterprises

Chart Epidemic Prevention Appropriation of Chinese Government, 2009-2012

Chart Some Occurrences of Porcine Reproductive and Respiratory Syndrome in China, 2012-2013

Chart Market Scale of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines, 2008-2012

Chart Tendering Procurement Result Publicity of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP-PRRS) Vaccines in Sichuan, 2013

Chart Tendering Procurement Result Publicity of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome (HP-PRRS) Vaccines in Guangdong, 2013

Chart China Major Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Producing Enterprises and Contact Information, 2012-2013

Chart Forecast on Pig Fattened Volume in China, 2013-2017

Chart Market Scale Forecast on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccines, 2013-2017


Related Reports

  • Research Report on China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry, 2014-2018China is the world's largest producer and consumer of pork with the output volume of pork accounting for nearly 50% of the total. The output volume of pork was 54.93 million tons in China in 2013, up by 2.8% YOY. The livestock volume of pigs was 474.11 million, down by 0.4% YOY while the stock volume of fattened pigs was 715.57 million, up by 2.5% YOY. The PRRS broke out in southern China and spread rapidly nationwide after summer in 2006, which lead to increases in mortality rate […]
  • Research Report on China Foot-and-mouth Disease (FMD) Vaccine Industry, 2014-2018China is the world's largest producer and consumer of pork with the output volume accounting nearly 50% of the total. According to the statistics of agricultural production from the National Bureau of Statistics of China, the annual output volume of poultry meat was 83.73 million tons in 2013, up by 1.8% YOY. The output volume of pork was 54.93 million tons, up by 2.8%. The stock volume of hogs was 474.11 million, down by 0.4% compared to 2012. The stock volume of fattened hogs was […]
  • Research Report on China Swine Fever Vaccine Industry, 2014-2018China is the world's largest producer and consumer of pork with the output volume accounting nearly 50% of the total. The output volume of pork was 54.93 million tons in China in 2013, up by 2.8% YOY. The livestock volume of pigs was 474.11 million, down by 0.4% YOY while the stock volume of fattened pigs was 715.57 million, up by 2.5% YOY. Swine fever is considered a highly infectious disease that needs strict prevention, control and extermination. The swine fever vaccine is one […]
  • Research Report on China Swine Fever Vaccine Industry, 2013-2017Swine fever is an acute, hyperpyretic and contagious disease, caused by swine fever viruses. Its incidence rate and death rate are both extremely high, and viruses can be transmitted at high speed. Immunization is the major measure to prevent swine fever. With the development of Chinese economy and increasing living standards of Chinese people, the demand for pork keeps growing accordingly. In 2012, the output volume of pork in China was 53.35 million tons, increasing by 5.6% YOY. […]
  • China Human Vaccine Industry Report, 2014-2017Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's […]